Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 24.23 -3.20% -0.80
ACAD closed down 3.2 percent on Monday, May 20, 2019, on 69 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ACAD trend table...

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Fell Below 20 DMA Bearish -3.20%
NR7 Range Contraction -3.20%
Fell Below 50 DMA Bearish -5.57%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -5.57%

Older signals for ACAD ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Chemistry Health Biopharmaceutical Pharmaceutical Industry Chemical Compounds Medication Alzheimer's Disease Schizophrenia Parkinson's Disease Glaucoma Chronic Pain Neurological Disorders Treatment Of Parkinson's Disease Treatment Of Alzheimer's Disease Treatment Of Glaucoma Allergan
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 28.67
52 Week Low 12.77
Average Volume 1,208,816
200-Day Moving Average 20.8462
50-Day Moving Average 25.8932
20-Day Moving Average 25.227
10-Day Moving Average 25.487
Average True Range 1.1139
ADX 13.35
+DI 18.4589
-DI 23.4935
Chandelier Exit (Long, 3 ATRs ) 23.5183
Chandelier Exit (Short, 3 ATRs ) 25.7917
Upper Bollinger Band 26.9677
Lower Bollinger Band 23.4863
Percent B (%b) 0.21
BandWidth 13.800293
MACD Line -0.0924
MACD Signal Line -0.0251
MACD Histogram -0.0673
Fundamentals Value
Market Cap 2.97 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -9.58
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.13
Resistance 3 (R3) 25.22 25.01 24.98
Resistance 2 (R2) 25.01 24.78 24.97 24.93
Resistance 1 (R1) 24.62 24.64 24.52 24.53 24.88
Pivot Point 24.41 24.41 24.36 24.37 24.41
Support 1 (S1) 24.02 24.18 23.92 23.93 23.58
Support 2 (S2) 23.81 24.04 23.77 23.53
Support 3 (S3) 23.42 23.81 23.48
Support 4 (S4) 23.33